FCGR2A and hematopoietic and lymphoid cell neoplasm: Elucidating the contribution of FcγR-binding to αTIGIT activity is crucial for the clinical development of these agents in hematological cancers, including MM, as mouse models have demonstrated necessity for FcγR binding in solid tumors (19).